Josep Sulé-Suso

Josep Sulé-Suso

Auto-generated profile, based on publicly available information

Josep Sulé-Suso

Keele University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2018 in The Analyst
Verified
Journal Article
Closed access
PDF file
Matthew J. BakerMatthew J. Baker
Matthew J. Baker
Hugh ByrneHugh Byrne
Hugh Byrne
JCJohn Chalmers
John Chalmers
PGPeter Gardner
Peter Gardner
RGRoyston Goodacre
Royston Goodacre
JSJosep Sulé-Suso
Josep Sulé-Suso
Vibrational spectroscopies, based on infrared absorption and/or Raman scattering provide a detailed fingerprint of a material, based on the chemical content. Diagnostic and prognostic tools based on these technologies have the potential to revolutionise our clinical systems leading to improved patient outcome, more efficient public services and significant economic savings. However, despite these strong drivers, there are many fundamental scientific and technological challenges which have limited the implementation of this technology in the clinical arena, although recent years have seen significant progress in addressing these challenges. This review examines (i) the state of the art of clinical applications of infrared absorption and Raman spectroscopy, and (ii) the outstanding challenges, and progress towards translation, highlighting specific examples in the areas of in vivo, ex vivo and in vitro applications. In addition, the requirements of instrumentation suitable for use in the clinic, strategies for pre-processing and statistical analysis in clinical spectroscopy and data sharing protocols, will be discussed. Emerging consensus recommendations are presented, and the future perspectives of the field are assessed, particularly in the context of national and international collaborative research initiatives, such as the UK EPSRC Clinical Infrared and Raman Spectroscopy Network, the EU COST Action Raman4Clinics, and the International Society for Clinical Spectroscopy.

23 October 2012 in The Analyst
Verified
Journal Article
Closed access
PDF file
ARAbigail Victoria Rutter
Abigail Victoria Rutter
TCThomas W. E. Chippendale
Thomas W. E. Chippendale
YYYing Yang
Ying Yang
PŠPatrik Španěl
Patrik Španěl
DSDavid Smith
David Smith
JSJosep Sulé-Suso
Josep Sulé-Suso
Our previous studies have shown that both lung cancer cells and non-malignant lung cells release acetaldehyde in vitro. However, data from other laboratories have produced conflicting results. Furthermore, all these studies have been carried out in 2D models which are less physiological cell growth systems when compared to 3D models. Therefore, we have carried out further work on the release of acetaldehyde by lung cells in 3D collagen hydrogels. Lung cancer cells CALU-1 and non-malignant lung cells NL20 were seeded in these hydrogels at different cell concentrations and the release of acetaldehyde was measured with the Selected Ion Flow Tube Mass Spectrometry (SIFT-MS) technique. The data obtained showed that the amount of acetaldehyde released by both cell types grown in a 3D model is higher when compared to that of the same cells grown in 2D models. More importantly, acetaldehyde from the headspace of lung cancer cells could be measured even at a low cell concentration (105 cells per hydrogel). The differential of acetaldehyde release could be, depending on the cell concentration, more than 3 fold higher for cancer cells when compared to non-malignant lung cells. This pilot study is the first to study acetaldehyde emission from albeit only two cell types cultured in 3D scaffolds. Clearly, from such limited data the behaviour of other cell types and of tumour cells in vivo cannot be predicted with confidence. Nevertheless, this work represents another step in the search for volatile biomarkers of tumour cells, the ultimate goal of which is to exploit volatile compounds in exhaled breath and other biological fluids as biomarkers of tumours in vivo.

6 August 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
MKMustafa Kansiz
Mustafa Kansiz
LDLewis M. Dowling
Lewis M. Dowling
IYIbraheem Yousef
Ibraheem Yousef
OGOlivier Guaitella
Olivier Guaitella
Ferenc BorondicsFerenc Borondics
Ferenc Borondics
JSJosep Sulé-Suso
Josep Sulé-Suso

1 January 2019 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
JSJosep Sulé-Suso
Josep Sulé-Suso
NWNick A Watson
Nick A Watson
DPDaniel G van Pittius
Daniel G van Pittius
AJApurna Jegannathen
Apurna Jegannathen
In spite of new drugs, lung cancer is associated with a very poor prognosis. While targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow-up. Thus, new drugs or re-evaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both in vitro and in vivo is being carried out, it is important to be attentive to patients where the disease responds to treatments not considered standard in clinical practice. We report here a patient with adenocarcinoma of the lung who, after declining chemotherapy and radiotherapy, presented with tumour response following self-administration of cannabidiol, a non-psychoactive compound present in Cannabis sativa. Prior work has shown that cannabidiol may have anti-neoplastic properties and enhance the immune response to cancer. The data presented here indicate that cannabidiol might have led to a striking response in a patient with lung cancer.

20 May 2014 in Cytometry Part A
Verified
Journal Article
Closed access
PDF file
ARAbigail Victoria Rutter
Abigail Victoria Rutter
MSMuhammad R. Siddique
Muhammad R. Siddique
JFJacob Filik
Jacob Filik
CSChristophe Sandt
Christophe Sandt
PDPaul Dumas
Paul Dumas
JSJosep Sulé‐Suso
Josep Sulé‐Suso

9 July 2013 in The Analyst
Verified
Journal Article
Closed access
PDF file
JPJacek K. Pijanka
Jacek K. Pijanka
NSNick Stone
Nick Stone
ARAbigail Victoria Rutter
Abigail Victoria Rutter
NFNicholas Forsyth
Nicholas Forsyth
GSGanesh D. Sockalingum
Ganesh D. Sockalingum
JSJosep Sulé-Suso
Josep Sulé-Suso
Raman spectroscopy has been widely used to study its possible clinical application in cancer diagnosis. However, in order to make it into clinical practice, it is important that this technique is able not only to identify cancer cells from their normal counterparts, but also from the array of cells present in human tissues. To this purpose, we used Raman spectroscopy to assess whether this technique was able to differentiate not only between lung cancer cells and lung epithelial cells but also from lung fibroblasts. Furthermore, we studied whether the differences were due to cell lineage (epithelial versus fibroblast) or to different proliferative characteristics of cells, and where in the cell compartment these differences might reside. To answer these questions we studied cell cytoplasm, cell nucleus and isolated whole cell nuclei. Our data suggests that Raman spectroscopy can differentiate between lung cancer, lung epithelial cells and lung fibroblasts. More important, it can also differentiate between 2 cells from the same lineage (fibroblast) but with one of them rendered immortal and with an increased proliferative activity. Finally, it seems that the main spectral differences reside in the cell nucleus and that the study of isolated nuclei strengthens the differences between cells.